MariTide vs Tirzepatide
A once-monthly antibody-peptide conjugate in Phase 3 (up to 20 percent weight loss at 52 weeks in its Phase 2 trial) versus the approved once-weekly dual agonist (about 21 percent at 72 weeks in SURMOUNT-1).
Maridebart Cafraglutide (MariTide, AMG 133)
Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight loss in Phase 2.
Tirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
| Attribute | MariTide | Tirzepatide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3) | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) |
| Half-life | Weeks (monthly dosing) | ~5 days |
| Molecular weight | Peptide-antibody conjugate | 4,813.5 Da |
| Mechanism | Activates the GLP-1 receptor while blocking the GIP receptor, delivered as a long-acting peptide-antibody conjugate for monthly dosing. | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. |
| Legal status (US) | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between MariTide and Tirzepatide?
MariTide: Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight loss in Phase 2. Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Which has stronger research evidence, MariTide or Tirzepatide?
MariTide is rated Moderate and Tirzepatide is rated Strong for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are MariTide and Tirzepatide FDA-approved?
MariTide: Investigational (Phase 3). Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea).
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.